Needham & Company Reiterates a 'Buy' on Pharmacyclics (PCYC); Ibrutinib Continues to Demonstrate Impressive Efficacy/Safety
Tweet Send to a Friend
Needham & Company reiterates a 'Buy' on Pharmacyclics (NASDAQ: PCYC) price target of $34.00.
Analyst, Alan Carr, said, "Additional ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Alan Carr, said, "Additional ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
